Publication:
The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: The St. Jude children's research hospital experience

dc.contributor.authorLisa M. McGregoren_US
dc.contributor.authorBhaskar N. Raoen_US
dc.contributor.authorAndrew M. Davidoffen_US
dc.contributor.authorCatherine A. Billupsen_US
dc.contributor.authorSuradej Hongengen_US
dc.contributor.authorVictor M. Santanaen_US
dc.contributor.authorD. Ashley Hillen_US
dc.contributor.authorChristine Fulleren_US
dc.contributor.authorWayne L. Furmanen_US
dc.contributor.otherSt. Jude Children Research Hospitalen_US
dc.contributor.otherUniversity of Tennessee Health Science Centeren_US
dc.contributor.otherWashington University School of Medicine in St. Louisen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-06-21T08:07:32Z
dc.date.available2018-06-21T08:07:32Z
dc.date.issued2005-12-15en_US
dc.description.abstractBACKGROUND. It remains unclear whether primary tumor resection benefits patients with metastatic neuroblastoma. The authors assessed the impact of extent and timing of resection on outcome in these patients. METHODS. The authors reviewed the records of 124 patients > 1 year of age at diagnosis of International Neuroblastoma Staging System Stage 4 neuroblastoma. The survival estimates of those who did and did not have a gross total resection (GTR) and of those who had initial versus delayed GTR were compared. Surgical complications were reviewed. RESULTS. The 5-year survival estimates were comparable for the 90 patients who had a GTR and the 17 who underwent surgery but did not have a GTR (29.9% ± 5.1% [standard error] vs. 29.4% ± 10.1%). The 7 patients who underwent GTR at the time of diagnosis had a higher 5-year survival estimate than the 83 patients who had a GTR after induction chemotherapy (83.3% ± 13.9% vs. 25.2% ± 5.0%) (P = 0.001). Five-year event-free survival estimates were similarly higher in the initial-GTR group (57.1% ± 18.7% vs. 14.5% ± 4.2%) (P = 0.002). These two groups did not differ significantly in age at diagnosis (P = 0.118), site of primary tumor (P = 0.34), MYCN amplification status (P = 1), serum lactate dehydrogenase activity at diagnosis (P = 0.34), or treatment protocol (P = 0.22). Twenty-two (21%) patients had a surgical complication. CONCLUSIONS. In this small cohort of patients with metastatic neuroblastoma, GTR at the time of diagnosis offered a survival benefit. Further prospective studies are warranted before this approach can be applied to all patients with metastatic neuroblastoma. © 2005 American Cancer Society.en_US
dc.identifier.citationCancer. Vol.104, No.12 (2005), 2837-2846en_US
dc.identifier.doi10.1002/cncr.21566en_US
dc.identifier.issn0008543Xen_US
dc.identifier.other2-s2.0-29144520567en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/16256
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=29144520567&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleThe impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: The St. Jude children's research hospital experienceen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=29144520567&origin=inwarden_US

Files

Collections